Olon

Olon is a global pharmaceutical ingredients company headquartered in Rodano, Italy, specializing in the development and production of active pharmaceutical ingredients (APIs). The company operates as a fully integrated contract development and manufacturing organization (CDMO) while also serving as a leading international supplier of generic APIs. Its business is built on two complementary pillars: custom development and manufacturing services for pharmaceutical partners, and a mature commercial portfolio of generic APIs supported by a continuously expanding R&D pipeline. Olon's technological foundation combines advanced chemical synthesis with microbial biomanufacturing and semi-synthesis approaches. This integrated capability allows the company to handle a broad variety of molecule types, from early-phase drug discovery through to commercial market supply. Its facilities feature multi-purpose and dedicated production lines designed for varying levels of containment, including ultra-high-containment for high-potency and highly toxic compounds (HPAPIs). The company describes itself as having one of the longest track records in the API industry. Its global network comprises 14 manufacturing sites and 14 R&D centers worldwide, supported by approximately 2,800 professionals, including 350 R&D specialists. This international footprint enables Olon to deliver innovation, reliability, and technical excellence across all stages of development and production. Olon supports treatments across major therapeutic areas and contributes to the manufacture of numerous breakthrough pharmaceutical products, including retinoids, antineoplastics, cardiovascular and metabolic disease compounds, antibiotics, and antivirals. The company positions itself as a reliable, flexible, and innovative partner operating to the highest international standards of safety, quality, and environmental responsibility. As a CDMO, Olon offers dedicated GMP solutions for the development and manufacturing of new chemical entities (NCEs), advanced intermediates, and building blocks. As a generic API supplier, it serves clients with a mature commercial portfolio designed to meet first-to-market generic product opportunities. The company's dual model allows it to serve both innovator pharmaceutical companies and generic drug manufacturers on a global scale.

Olon is an Italian-headquartered pharmaceutical ingredients company with a long history in the API industry. The company has evolved into a global partner for the development and manufacturing of active pharmaceutical ingredients, serving both CDMO and generic markets. Its growth has been driven by the integration of advanced chemical synthesis with biological processes, allowing it to operate to the highest international standards of safety, quality, and environmental responsibility. Over the decades, Olon has built one of the longest track records in the API industry. It has expanded its global network to include 14 manufacturing sites and 14 R&D centers worldwide, supported by approximately 2,800 professionals, among them 350 R&D specialists. This international presence enables the company to deliver innovation, reliability, and technical excellence at every stage of development and production. The company's capabilities span custom chemical synthesis and microbial fermentation, providing flexible, scalable solutions tailored to each project's specific requirements. Its facilities feature multi-purpose and dedicated production lines designed to handle varying levels of containment, including ultra-high-containment for high-potency and highly toxic compounds. Through structured expertise in chemical synthesis and microbial biomanufacturing, Olon stands among the leading international producers of APIs and HPAPIs. Olon supports treatments across major therapeutic areas and contributes to the manufacture of numerous breakthrough pharmaceutical products, including retinoids, antineoplastics, cardiovascular and metabolic disease compounds, antibiotics, and antivirals. As a CDMO, it offers dedicated GMP solutions for the development and manufacturing of NCEs, advanced intermediates, and building blocks. As a generic API supplier, it supports clients with a mature commercial portfolio and a continuously expanding R&D pipeline designed to meet first-to-market generic product opportunities.

Global leader in API development and manufacturing, combining chemical synthesis and biomanufacturing to serve CDMO partners and generic markets with reliability, flexibility, and innovation.

• Generic APIs

  A mature commercial portfolio of generic active pharmaceutical ingredients, supported by an expanding R&D pipeline designed for first-to-market opportunities.

• CDMO Services

  Fully integrated contract development and manufacturing services from early-phase drug discovery to market supply, across a broad variety of molecule types.

• High-Potency APIs (HPAPIs)

  Manufacturing of high-potency and highly toxic compounds using ultra-high-containment facilities.

• Advanced Intermediates and Building Blocks

  GMP-grade intermediates and building blocks for pharmaceutical development and manufacturing.

• 2021.09.07

  Reported2021.09.07

  Olon announces expansion of Italian manufacturing site[4]Olon宣布扩建意大利生产基地prnewswire.com

  Olon announced a major expansion of its Settimo Torinese site in Italy, including a new area that will produce proteins using microbial fermentation.

Read more

1. 1OLON - Leading International API Manufacturing Companyolonspa.com
2. 2The Company - Leading International API supplierolonspa.com
3. 3Olon - Wikidatawikidata.org
4. 4Olon宣布扩建意大利生产基地prnewswire.com